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The aim of this study is to define the relationship between the tyrosinase expression in the peripheral blood and the clinical course of
the disease in stage III disease-free melanoma patients after radical lymph node dissection. RT–PCR techniques were used to identify
tyrosinase mRNA in 110 patients; a total of 542 blood samples were investigated. In all, 54 patients (49%) showed at least one
positive result; 13 patients (11.8%) showed baseline positive results: six became negative thereafter, whereas seven showed follow-up
positive results until disease progression occurred. One or more positive determinations were found during follow-up in 41 patients
with negative baseline tyrosinase. No correlation was found between baseline results and the relapse rate or disease-free survival
(DFS), whereas a significant correlation was found between positive tyrosinase results and disease recurrence during follow-up. In
fact, 72.9% of positive patients relapsed, but only 19.3% of negative cases did so. The median interval between the positive results and
the clinical demonstration of the relapse was 1.9 months (range 1–6.6). Disease-free survival multivariate analysis selected, as
independent variables, Breslow thickness (P¼0.05), lymph node involvement according to the AJCC classification (P¼0.05) and
tyrosinase expression (P¼0.0001). In conclusion, RT–PCR tyrosinase mRNA expression is a reliable and reproducible marker
associated with a high risk of melanoma progression and we encourage its clinical use in routine follow-up.
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Tyrosinase, the monoxygenase responsible for the first two steps
of melanin biosynthesis (Battayani et al, 1993), is one of the
most specific enzymes involved in melanocytic differentiation.
Its role as a molecular marker in melanoma patients was first
proposed by Smith et al (1991) in the early 1990s; since
then, tyrosinase expression has been applied for the detection of
malignant melanoma cells in sentinel lymph node biopsies
and investigated in peripheral blood, bone marrow and biological
fluids (Ghossein et al, 1998; Blaheta et al, 2001; Hoon et al,
2001).
Several studies (Curry et al, 1998; Farthman et al, 1998; Ghossein
et al, 1998; Alao et al, 1999; Reinhold et al, 2001) have suggested a
potential clinical use of the RT–PCR analysis of tyrosinase mRNA
to detect circulating neoplastic cells in the peripheral blood
of melanoma patients. In a previous paper (Osella-Abate et al,
2000), we demonstrated that the majority of untreated stage IV
melanoma patients were positive, whereas chemotherapy admin-
istration was able to reduce tyrosinase rate, suggesting that
tyrosinase may provide a measure of therapy response and be a
predictor of disease evolution. However, the prognostic role of
tyrosinase expression in the peripheral blood of melanoma
patients after the excision of primary lesion and/or nodal
dissection has not yet been fully clarified. The meta-analysis
performed by Tsao et al (2001) suggests that, at the present time,
RT–PCR for tyrosinase mRNA is of limited value given the
unreliability of the procedure and the lack of data on the outcome
of stage I–III positive patients. More recently, Mellado et al (2002)
and Gogas et al (2002) showed that the detection of tyrosinase
mRNA in disease-free melanoma patients treated with adjuvant
interferon (IFN) is associated with an increased risk of relapse and
shorter disease-free survival (DFS).
In this study, tyrosinase mRNA expression has been prospec-
tively evaluated, immediately after surgical treatment and during
follow-up, in 110 stage III disease-free melanoma patients, with the
aim of defining the relationship between the tyrosinase detection
and the clinical course of the disease.
PATIENTS, MATERIALS AND METHODS
Patient population
A total of 110 patients with stage III melanoma graded according
to the new AJCC classification (Balch et al, 2000) (five stage IIIA,
44 stage IIIB, 61 stage IIIC) were enrolled into this study after
obtaining informed consent. Inclusion criteria were: (1) radical
lymph node dissection (elective, curative or selective) within 3–6
weeks; (2) histological evidence of nodal melanoma micro- or
macrometastases; (3) no clinical or radiological evidence of disease
at study entry. The clinical characteristics of these patients are
reported in Table 1. Received 5 February 2003; revised 9 June 2003; accepted 24 June 2003
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(94 patients; 85.4%) underwent adjuvant treatment with biological
response modifiers, according to different nonrandomised pilot
trials.
The follow-up schedule was based on clinical examinations
every 3 months for the first 3 years after lymph node dissection,
every 4 months in the fourth and fifth year, and every 6 months
thereafter. Baseline staging procedures for all patients included
chest X-rays, abdomen ultrasound, brain, lung and abdomen CT
scan, and total-body bone scintigraphy. Chest X-rays and abdomen
ultrasound were performed every 6 months for the first 3 years and
every 12 months thereafter, and brain, lung and abdomen CT scan
were performed every year for the first 3 years, and every 2 years
thereafter. Follow-up visits were anticipated in the presence of a
clinical doubt of recurrence or on the basis of patients’ requests.
The follow-up schedule was continued according to plan even in
the presence of tyrosinase results.
The first tyrosinase RT–PCR on peripheral blood test (baseline
determination) was performed within 3–6 weeks after surgical
treatment of regional nodal metastases in all patients (baseline
condition). During follow-up, tyrosinase samples were taken at
each visit every 3 months for the first 3 years and every 4 months
thereafter, or until disease progression.
In all, 50 volunteer age- and sex-matched healthy subjects were
used as the control group.
Blood preparation, RNA extraction and RT–PCR
A volume of 15ml of blood was obtained from both the groups and
collected in EDTA(K3) tubes. The first few millilitres of each blood
sample was discarded to avoid any possible contamination by
normal skin melanocytes. Blood samples were processed within 2h
after collection. The RNA extraction, yield and nested RT–PCR
procedures have been described elsewhere (Osella-Abate et al,
2000) and all standard steps were taken to prevent carry-over
contamination. A negative control (RNA from healthy donors
blood) and a positive control (RNA from a melanoma cell line)
(Osella-Abate et al, 2000) were included with each batch of samples
to verify a contamination–free environment and a faultless RT–
PCR operating system. The integrity of the RNA for each sample
was verified by RT–PCR with primers for human glyceraldehyde
3-phosphate dehydrogenase (GAPDH), as described elsewhere
(Osella-Abate et al, 2000).
Preclinical sensitivity testing
The positive control was performed using a melanoma cell line
derived from a subcutaneous metastasis, established and char-
acterised in our laboratory (Salomone et al, 2000). The same cell
line was used to evaluate the sensitivity and reproducibility of RT–
PCR with spiking experiments. Duplicate mixtures of mononuclear
cells prepared from 10ml of peripheral blood donated by healthy
volunteers were spiked with 10
4,1 0
3,1 0
2, 10, 1, and 0 melanoma
cells. RNA was extracted from these samples and the cDNA
synthesised and analysed by RT–PCR. Three sets of experiments
were performed. The detection limit was 1 melanoma cell in 10ml
of blood (Osella-Abate et al, 2000).
Statistical analysis
Statistical analyses were performed using the BMDP Statistical
Software. The values for each variable were given as mean7s.d.
Both parametric (w
2- and t-test) and nonparametric (Wilcoxon test
and Mann–Whitney test) tests were used to evaluate any
differences between the parameters examined; only ‘P-values’ of
parametric tests were reported, as the results of the two types of
tests were similar.
Disease-free survival was calculated as the time from the
baseline tyrosinase sample to the date of progression or last
check-up for all patients. Life-table estimates of DFS were derived
by the Kaplan–Meier method (Kaplan and Meier, 1958) and
statistical comparison was performed by the log-rank Mantel test
(Mantel, 1966). The relationship between DFS and prognostic
factors was determined by the Cox proportional hazard regression
model (Cox, 1972), with a stepwise selection of the significant
variables. The two assumptions of the Cox proportional hazard
Table 1 Clinical characteristics of patients
Stage Patients Gender Age (years) Samples Site of primary lesion (n) Breslow thickness (mm)
MF M F
IIIA 5 2 3 43.5 49 32 Upper extremities (1) 3.7271.63
(range 34–53) (range 34–60) Lower extremities (4)
IIIB 44 23 21 56 49 245 Head (4) 3.1773.19
(range 31–74) (range 27–61) Upper extremities (4)
Lower extremities (15)
Abdomen (2)
Back (18)
Others* (1)
IIIC 61 30 31 54.5 54 265 Head (3) 3.5173.11
(range 24–61) (range 21–82) Upper extremities (6)
Lower extremities (24)
Abdomen (6)
Back (20)
Others* (2)
Total 110 55 55 55 51 542 Head (7) 3.5773.08
(range 27–75) (range 21–82) Upper extremities (11)
Lower extremities (43)
Abdomen (8)
Back (38)
Others* (3)
*Including mucosal melanoma.
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underlying hazard function and the log-linear function of the
covariates (the proportionality assumption), and thus the ratio of
the hazard functions for any two patients with different sets of
covariates, does not depend on time. (2) The effects of covariates
upon the hazard function is log-linear. Six variables were included
in the multivariate model: tyrosinase expression, extension of
lymph node involvement (according to the AJCC classification),
Breslow thickness, gender, age and treatment (treated/untreated).
Breslow thickness and age were included as continuous variables,
whereas the others were categorical. Two different DFS multi-
variate analyses were performed according to tyrosinase expres-
sion, the first including baseline RT–PCR, and the second
including, follow-up results. In the second analysis, a patient was
considered tyrosinase positive in the presence of at least one
positive determination during follow-up.
RESULTS
Clinical results
After a median follow-up of 20. 3 months (range 3–48.3), 47 out of
110 stage III patients (42.7%) relapsed. The median DFS was 14.1
months (range 3–48.3).
The majority of relapsed patients developed distant metastases
(34 out of 47, 72.3%); 10 had soft tissue and 24 visceral
localizations. Only 13 (27.7%) patients developed a loco-regional
relapse (Table 2): four had local recurrence, seven ‘in transit’
metastases and two a regional node relapse. At the time of writing,
no clinical evidence of visceral metastases has been found in any
of these patients. No clinical benefit in terms of both relapse
rate and DFS was observed in patients who underwent adjuvant
treatments.
Tyrosinase results
All the samples obtained from healthy volunteers were negative for
tyrosinase mRNA. A total of 542 blood samples from 110
melanoma patients were investigated. A median of five tyrosinase
determinations for each patient was carried out (range 2–17)
with a median time to monitoring of 12.3 months (range 3–43
months).
In all, 54 patients (49%) showed at least one positive tyrosinase
RT–PCR result (75 out of 542 samples, 13.8%). Overall, 35 patients
had only one positive determination and 19 had two or more;
among this latter group, the positive determinations were
consecutive in 10 patients. According to the time occurrence, six
patients were positive at baseline conditions and negative there-
after throughout the follow-up period, whereas seven showed
baseline and follow-up positive results until disease progression
occurred. One or more positive determinations were found during
follow-up in the 41 patients who had a negative baseline
tyrosinase. On the contrary, all the determinations performed in
the other 56 patients were always negative. An increase in the
percentage of positive samples was found from stage IIIA (two out
of 32 samples; 6.2%) to IIIB (26 out of 245; 10.6%) up to IIIC
patients (47 out of 265; 17.7%).
Baseline tyrosinase results and clinical course
Only 13 patients (11.8%) showed baseline positive results; the
majority of them (nine out of 13) were stage IIIC. Seven of these 13
patients developed a relapse; all these patients showed evidence of
circulating melanoma cells throughout follow-up until clinical
evidence of disease progression, whereas there was no evidence of
recurrence in the six patients who had only baseline positive
results followed by negative samples.
No statistically significant difference in the relapse rate was
found between patients with baseline positive (Seven out of 13;
54%) and negative results (40 out of 97; 41%) (w
2¼0.319,
P¼0.572). The DFS multivariate analysis showed that the
independent variables with a statistical prognostic significance
were Breslow thickness (P¼0.0098) and the extension of the
lymph node involvement, according to the AJCC classification
(P¼0.0067) (Table 3); baseline tyrosinase results did not influence
the outcome of the disease (P¼0.1302).
Table 2 Sites of recurrence
No of patients IIIB IIIC
Site of metastasis Positive Negative Positive Negative Positive Negative
Loco-regional metastasis 9 4 2 2 7 2
No of metastatic sites
Distant metastasis 26 8 ¼1 631 25
412 0 6 0
Total 35 12 10 5 25 7
Table 3 Multivariate analysis results
Variable Coefficient Standard error Risk ratio P-value
(A)
AJCC 0.8081 0.2983 2.2436 0.0067
Breslow thickness 0.0010 0.0004 1.0010 0.0098
Baseline tyrosinase* 0.6345 0.4192 1.8860 0.1302
(B)
AJCC 0.6186 0.3168 1.8563 0.05
Breslow thickness 0.0007 0.0004 1.0007 0.05
Follow-up tyrosinase* 1.4678 0.3662 4.3399 0.0001
*Tyrosinase negative¼0, Tyrosinase positive¼1.
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In all, 62 patients had negative tyrosinase results during follow-up,
six of whom were positive at baseline conditions and negative
thereafter. The remaining 48 patients showed at least one positive
determination during follow-up and a statistically significant
correlation was found between positive tyrosinase results and
disease recurrence. In fact, a relapse occurred in 35 out of 48
positive (72.9%, 10 stage IIIB, 25 stage IIIC), and in only 12 out of
62 negative patients (19.3%, five stage IIIB, Seven stage IIIC)
(w
2¼29.566, Po0.0001) (Figure 1). Moreover, nine out of 10
patients with two consecutive positive determinations developed a
visceral relapse.
Distant metastases occurred in 26 out of 35 relapsed tyrosinase
positive (74.3%) and in eight out of 12 relapsed negative patients
(66.7%) (Table 2). No significant difference was found in
the tyrosinase expression of treated/untreated patients.
The median interval between the finding of positive tyrosinase
results and the demonstration of the relapse was 1.9 months (range
1–6.6). At the time of writing, 13 out of 48 positive patients
have not relapsed. The positive determination was followed by
repeated negative samples in these patients. The median follow-up
from the last positive determination is, to date, 13 months (range
3–35).
The sensitivity of the assay (the probability that a positive
patient would develop disease recurrence) was 74.5% (95%
CI 63.3–83.3%), the specificity (the probability that a negative
patient would remain disease-free) was 79.4% (95% CI 71.0–
86.0%), the positive predictive value was 72.9% (95% CI
61.9–81.6%) and the negative predictive value was 80.6% (95%
CI 72.1–87.4%).
The median DFS of follow-up tyrosinase-positive patients
was significantly lower than that of negative patients (11.4 months
vs 4 48.3 months, Po0.001) (Figure 2). When patients with
only one positive result were compared to those with two, whether
consecutive or not, there was no significant difference in
DFS. However, the median DFS of positive patients both
at baseline and during follow-up was significantly lower
when compared to that of positive patients at baseline only
or positive during follow-up only (Po0.001). Moreover,
the median DFS of patients with two consecutive positive
determinations was significantly lower than that of patients
with two, not consecutive determinations (P¼0.0188). Disease-
free survival FS multivariate analysis was carried out including
the RT–PCR results during follow-up instead of baseline.
The stepwise model selected as independent variables
not only Breslow thickness (P¼0.05) and extension of
lymph node involvement according to the AJCC classifica-
tion (P¼0.05) but also the tyrosinase expression (P¼0.0001)
(Table 3).
DISCUSSION
In this study, the RT–PCR technique was used to detect the
presence of tyrosinase mRNA in the peripheral blood of a cohort of
110 stage III disease-free melanoma patients, both at diagnosis and
during follow-up, until disease progression. The tyrosinase
expression was related with the clinical course, in an attempt to
ascertain if the finding of circulating melanoma cells is associated
with a higher relapse rate and/or shorter DFS. Our preliminary
results (Osella-Abate et al, 2000, 2002) suggested a significant
relationship between the tyrosinase expression and disease
outcome, inasmuch as the progression rate was significantly
higher, and the DFS significantly lower in positive patients with
respect to the negative ones.
Even if tyrosinase expression in the peripheral blood of
melanoma patients has been widely reported in the literature,
only a few papers have been specifically addressed to the
evaluation of tyrosinase expression both at diagnosis and during
the follow-up of stage III disease-free patients. This is of clinical
relevance, inasmuch as the majority of disease progressions take
place in these patients in visceral sites due to the haematogenous
spreading of metastatic cells. Moreover, the monitoring of
tyrosinase expression in the peripheral blood could play a relevant
role in the evaluation of adjuvant treatments.
There is no agreement in the literature as to the percentage of
positive tyrosinase determinations in stage III patients, with a wide
range of values up to 60%, according to the different studies
(Brossart et al, 1993; Kunter et al, 1996; Pittman et al, 1996; Glaser
et al, 1997; Farthman et al, 1998; Proebstle et al, 2000; Reinhold
et al, 2001). Our results showed a positive tyrosinase expression in
49% of patients. Moreover, the majority of them developed
evidence of circulating melanoma cells during follow-up, whereas
only 13 (12%) had positive baseline determinations. Mellado et al
(2002) reported similar results in a cohort of 50 stage III patients
treated with adjuvant IFN, showing positive results in 12% before
treatment and 46% during follow-up. On the other hand, Gogas
et al (2002) found a higher percentage of positive results before
treatment (50%) in 60 stage IIB–III disease-free patients.
The results of the present study show a striking correlation
between the tyrosinase expression during follow-up and the
clinical outcome of the disease. In fact, more than 70% of our
patients with at least one positive tyrosinase determination during
follow-up relapsed, while only less than 20% of patients with
constant negative samples did so. The relationship was even more
evident when patients with two consecutive positive determina-
tions were considered: all but one (nine out of 10) developed a
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Figure 1 Correlation between tyrosinase results during follow-up and
clinical course. A relapse occurred in 35 out of 48 positive (72.9%, 10 stage
IIIB, 25 stage IIIC), and in only 12 out of 62 negative patients (19.3%, five
stage IIIB, seven stage IIIC) (w
2¼29.566, Po0.0001). ’, PD (progressive
disease); &, DF (disease free).
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Figure 2 RT–PCR results during follow-up and DFS. Disease free
survival was calculated by the Kaplan–Meier method. The statistical
significance of the difference in DFS between (A) RT-PCR-negative (’)
and (B) RT–PCR-positive (m) patients was calculated by the log-rank test
(Po0.001).
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previous data (Osella-Abate et al, 2002), tyrosinase expression was
found to play an independent prognostic role in influencing DFS,
together with the extension of nodal involvement and the Breslow
thickness of the primary tumour. The association between
tyrosinase results and clinical outcome is also demonstrated by
the early detection of disease recurrence after a positive
determination. In our experience, this interval is lower (median
1.9 months) than that reported by Gogas (21 months) (Gogas et al,
2002), even if, according to the study design, follow-up investiga-
tions were anticipated only at the patients’ request or due to
clinical doubt, and not on the basis of tyrosinase results.
The metastatic pattern of relapse, with a higher incidence of
visceral localisations in positive than in negative patients, confirms
that tyrosinase expression is significantly associated with
the haematogenous metastatic pathway. Our data do not provide
more insights as to the origin of metastatic spreading in tyrosinase
negative patients. Even if it cannot be excluded that the failure to
detect circulating melanoma cells may depend on the sensitivity
of the technique, the literature data show that tumour cells
persist only transiently in the peripheral blood, as demonstrated
by sequential analyses taken at a few hour-intervals from the
same patients (Reinhold et al, 1997). The intermittent shedding
of tyrosinase-positive cells in the bloodstream may, therefore,
explain the discrepancies observed in patients with visceral
relapses.
The intriguing hypothesis that the occurrence of circulating
melanoma cells in apparently disease-free patients could constitute
the early phase of the metastatic spreading, rather than a
consequence of a well-established metastatic localisation, is
indirectly confirmed by the finding of tyrosinase-positive results
also in a subgroup of patients who have not developed a
recurrence to date. Indeed, in our series, 35% of patients showed
positive tyrosinase results, preceded or followed-up by one or
more negative determinations, and have not developed a clinically
objectivable disease recurrence after a median follow-up of more
than 1 year.
The biological significance of these findings is still poorly
understood. It is not conceivable to associate a metastatic
spreading with a positive tyrosinase finding detected more than
1 year before, as all the relapses in positive patients from our series
occurred within 6 months from the last positive determination.
The conversion from a positive to one or more negative
determinations during follow-up could be a consequence of
adjuvant treatment, as suggested by Mellado et al (2002). Also in
our experience, all the positive patients not yet relapsed became
negative while under adjuvant treatment. Alternatively, it could be
hypothesised that other factors may play a role in inducing and/or
inhibiting metastatic growth. Therefore, our previous findings that
patients with positive tyrosinase results and high VEGF serum
levels show a significantly worse prognosis than those with positive
results, but normal VEGF levels, suggest that the modulation of
neoangiogenic factors constitutes a crucial key point in early
metastatic development (Osella-Abate et al, 2002).
In conclusion, the good sensitivity and specificity of the
RT–PCR assay, in spite of the possibility that a transient shedding
of melanoma cells in the bloodstream could give rise to a false
negative determination, confirm that tyrosinase expression is a
reliable and easily reproducible marker associated with a higher
risk of melanoma progression. We encourage its clinical use in
the routine follow-up of melanoma patients. Moreover, we feel
that accurate clinical examinations should be carried out together
with radiological procedures in the presence of a positive
tyrosinase determination, even in the absence of symptoms.
Adequate follow-up guidelines for positive patients should be
planned, allowing for early observation of any metastasis. From a
clinical point of view, we suggest that at least chest X-rays and
abdomen ultrasound be carried out and, if negative, that a
tyrosinase determination be repeated at a 1-month interval. Brain,
lung and abdomen CT, together with bone marrow scintigraphy,
should be performed in the presence of a persistent positive
determination.
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